Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 9/20 | 0.55 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | ITK | Q08881 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | BCL6 | P41182 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004937 | 0.90 | SYK (0.56) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL4001315 | 0.87 | AURKA (0.55) | SYKEGFRITKCDK2BCL6 | |
| SCHEMBL4000371 | 0.86 | SYK (0.55) | SYKEGFRITKCDK2BCL6 | |
| SCHEMBL4000118 | 0.85 | SYK (0.62) | SYKEGFRITKCDK2BCL6 | |
| SCHEMBL4006621 | 0.81 | JAK3 (0.64) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL3997326 | 0.79 | SYK (0.62) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL4002645 | 0.79 | SYK (0.70) | SYKEGFRBTKITKCDK2 | |
| SCHEMBL3998382 | 0.78 | SYK (0.67) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL4002462 | 0.78 | JAK3 (0.56) | SYKEGFRBTKITKCCNT1 | |
| SCHEMBL3999309 | 0.78 | STK17A (0.52) | SYKEGFRBTKITKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904457-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | Rigel Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006133426-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |